Clinical TrialJun 1, 2026, 06:02 AM
Greenwich LifeSciences GLSI-100 Phase III Shows 70-80% Recurrence Reduction
AI Summary
Greenwich LifeSciences provided an update on its FLAMINGO-01 Phase III clinical trial for GLSI-100, reporting preliminary data showing an approximately 70-80% reduction in recurrence rate in the fully enrolled non-HLA-A*02 arm. The company also updated on its delayed Form 10-K filing for FY2025, attributing it to auditor coordination issues, stating the adjustments are not material. Greenwich LifeSciences reported an unaudited cash balance of approximately $10.5 million as of March 31, 2026, an improvement over 2025.
Key Highlights
- GLSI-100 Phase III preliminary data shows 70-80% reduction in recurrence rate in non-HLA-A*02 arm.
- Non-HLA-A*02 arm of FLAMINGO-01 trial is fully enrolled with 250 patients.
- DTH reactions increased by approximately 4x (290%) in the non-HLA-A*02 population after GLSI-100.
- Cash balance as of March 31, 2026, is approximately $10.5 million (unaudited).
- 2025 net cash used in operating activities was approximately $9.9 million (unaudited).
- Form 10-K for FY2025 is in final audit approval steps; delays due to dual auditor coordination.
- Company believes accounts payable adjustments are not material and do not change fundamentals.
Price Impact
More from GLSI